Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

While a fraction of cancer patients treated with anti–PD-1 show durable therapeutic responses, most remain unresponsive, highlighting the need to better understand and improve these therapies. Using an in vivo screening approach with a customized shRNA pooled library, we identified DDR2 as a leading...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Megan M., Lee, Francis Y. F., Jones, Robert T., Kimball, Abigail K., Saravia, Elizabeth, Graziano, Robert F., Coleman, Brianne, Menard, Krista, Yan, Jun, Michaud, Erin, Chang, Han, Abdel-Hafiz, Hany A., Rozhok, Andrii I., Duex, Jason E., Agarwal, Neeraj, Chauca-Diaz, Ana, Johnson, Linda K., Ng, Terry L., Cambier, John C., Clambey, Eric T., Costello, James C., Korman, Alan J., Theodorescu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382401/
https://www.ncbi.nlm.nih.gov/pubmed/30801016
http://dx.doi.org/10.1126/sciadv.aav2437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382401/
https://www.ncbi.nlm.nih.gov/pubmed/30801016
http://dx.doi.org/10.1126/sciadv.aav2437

Ejemplares similares